wound discharge (7 isolates), catheters (3 isolates), abdominal fluid (3 isolates), pleural fluid (1 isolate), and bile (1 isolate). The department distribution of the CREC isolates were as follows: intensive care units (ICUs; 32 patients), respiratory wards (9 patients), urology (7 patients), general surgery (3 patients), nephrology (3 patients), endocrinology (2 patients), cardiology (2 patients), neurology (2 patients), orthopedic surgery (2 patients), and neurosurgery (2 patients).
A case-control study was performed to define the risk factors associated with carbapenem-resistant Enterobacter cloacae. The 64 CREC patients were considered as the case group. The control group (patients infected by carbapenem-susceptible Enterobacter cloacae) included 2 controls per case patient according to treatment date, infection site, and the unit where the patient was treated. The parameters reviewed included age, sex, underlying diseases (diabetes mellitus, malignancy, gastrointestinal tract disease, cardiovascular disease, genitourinary tract disease, chronic pulmonary disease, chronic renal failure, liver disease, cerebrovascular disease, intraabdominal infection), prior antibiotic therapy (the use of antibiotics [quinolones, cefazolins, or/and aminoglycosides] for at least 2 weeks before a CREC culture result), recent surgery during the past 30 days, and exposure to invasive interventions (intravascular catheter, urinary catheter, mechanical ventilation, nasogastric tube, and parenteral nutrition) within 7 days before a CREC culture result.
Statistical analysis
Statistical analyses were performed using SPSS 15.0 (Chicago, IL, USA). Continuous variables were compared with Student's t-test. Categorical variables were compared by a chi-square test or Fisher's exact test. A P-value of less than 0.05 was considered to be significant.
Microbiological studies
Identification and antimicrobial susceptibility testing of the 666 Enterobacter cloacae strains were performed using a VITEK-2 compact automatic system (bioMerieux, France) according to the manufacturer's instructions. The strains identified with imipenem MIC of ≥2 µg/mL and/ or ertapenem MIC of ≥1 µg/mL by instrumental method were screened as possible CREC and were confirmed by an Etest (AB Biodisk, Sweden). The disc diffusion method was performed to determine resistance to some antimicrobial drugs ( Table 2 ). The interpretative criteria for antimicrobial susceptibility testing were set according to the Clinical Laboratory Standards Institute (CLSI) (8) . Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, E. coli ATCC 35218, K. pneumoniae ATCC 700603, and Enterococcus faecalis ATCC 29212 were used for quality control of susceptibility tests.
Molecular analysis
Detection of ESBL genes (including blaSHV, blaTEM, blaCTX-M-1, blaCTX-M-2, and blaCTX-M-9) and carbapenemase genes (including blaKPC, blaIMP, blaNDM-1, and blaVIM) was performed using polymerase chain reaction (PCR). Template DNA was extracted by the boiling preparation method (9) . The primers used for PCR are described in Table 3 . The PCR parameters were as follows: initial denaturation step at 94 °C for 5 min followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 40-56 °C for 30 s, and extension at 72 °C for 40 s, with a final extension step at 72 °C for 5 min. The PCR products were examined by electrophoresis in 1% agarose gels under UV light, purified and sequenced by Invitrogen (Invitrogen, Shanghai, China), and compared with known sequences available in the GenBank databases.
Pulsed-field gel electrophoresis (PFGE) of genomic DNA was carried out with a CHEF Mapper XA apparatus (Bio-Rad Laboratories, USA) to investigate the genetic relatedness among the CREC isolates. Genomic DNA was digested with XbaI (Takara Bio Inc., Japan). Electrophoresis conditions were as follows: 19 h at 6 V/cm and 14 °C with pulse times ranging from 2.2 to 54.2 s. PFGE patterns were interpreted according to the criteria determined by Tenover et al. (10) .
Results

Clinical characteristics of the CREC isolates
During the study period, 666 isolates of Enterobacter cloacae were identified at the study hospital. Of these, 64 (9.6%) isolates were defined as CREC. As shown in Table  1 , the total number of Enterobacter cloacae and CREC both presented growth trends during the 4 years. The prevalence of CREC increased from 2.8% in 2009 to 16.1% in 2012, and there was statistical significance between 2012 and the other years (P < 0.01). The 64 CREC were mainly from the bloodstream (22; 34.4%) and less frequently from other samples, such as sputum (17; 26.6%), urine (10; 15.6%), and wound discharge (7; 10.9%). Concerning the in- 
VIM TTATGGAGCAGCAACGATGT CAAAAGTCCCGCTCCAACGA 920 (14) hospital distribution, the majority of these CREC patients were from the ICU (32; 50.0%), followed by respiratory wards (9; 14.1%), and urology (7; 10.9%).
Risk factors associated with CREC patients
There were no significant differences in demographic characteristics and most clinical illnesses between the cases and controls (P > 0.05). A univariate analysis showed that CREC infections were associated with cerebrovascular disease, prior treatment with antibiotics, intravascular catheterization, urinary catheterization, mechanical ventilation, and parenteral nutrition while the control group was associated with chronic pulmonary disease (P < 0.05) ( Table 4 ). 
Antimicrobial susceptibility
PFGE analysis
The genetic relatedness of the CREC isolates was investigated by PFGE in our study. Lanes 3, 5, and 10 represented the same clone. All of the other isolates yielded different DNA band profiles, and no obvious clonal association was observed among them ( Figure) .
Discussion
Carbapenems are traditionally considered to be the last defense against serious infections caused by ESBLproducing Enterobacteriaceae. However, in recent years, CREC has been detected in several countries (11) (12) (13) . In the last 4 years, the numbers of CREC increased year by year. In 2012, 46 (16.1%) patients were diagnosed with CREC infections in our hospital, about 3 times that of the previous year (Table 1 ). According to PFGE results, significant clonal spread was not observed among most of them, showing that no outbreak of CREC happened during these 4 years. The increase of CREC may be associated with the intensive use of antibiotics, mutation of resistance genes, and horizontal trans fer of resistance genes (14, 15) . This finding suggests that effective measures should be taken to control the emergence and dissemination of CREC strains in health care organizations and communities. Evaluation of the risk factors for CREC infections demonstrated that invasive interventions were significantly associated with the CREC group (P < 0.05). This is likely due to the fact that invasive therapy can increase the chances of CREC infection and prolong the use of antibiotics. This result is similar to those of previous studies (16) (17) (18) . These findings suggest that prompt discontinuation of invasive interventions is an effective way to reduce the risk of CREC infections. The use of antibiotics, especially cephalosporins and carbapenems, was also a risk factor for CREC infection. It is worrisome that cephalosporins and carbapenems are frequently used to treat gram-negative Bacillus infections in hospitals and community settings. Empirical therapy with cephalosporins or carbapenems 
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Single carbapenemases may lead to the emergence of carbapenem-resistant strains (14, 15) . It is very important to choose suitable antibiotics according to drug sensitivity tests and avoid the abuse of antibiotics. In terms of disease prevalence, we found that cerebrovascular disease was more common in the case group, and chronic pulmonary disease was more prevalent in the control group (P < 0.05). Unfortunately, there is no additional research to determine whether there is a connection between the diseases in this study. In addition, we found that 50% of CREC patients came from ICU wards. The ICU is a special department, and most ICU patients have serious diseases, more opportunities for invasive treatment, and longer courses of antibiotic treatment; therefore, the ICU is another risk factor for CREC infections. In our study, 49 (76.6%) of CREC had carbapenemase genes, and KPC-2 was the most common carbapenemase type in the study hospital. Similar studies have been reported in different counties and different regions of China (19) (20) (21) . Different results were also reported in Chongqing in China. In another study, IMP and OXA were the most prevalent carbapenemases, and KPC-2 was not detected in their hospital (9) .
Ten years ago, ESBLs were mainly produced by Klebsiella pneumoniae and Escherichia coli. Now ESBLproducing Enterobacter cloacae have been reported in many countries (22) (23) (24) . This study found that 39 (60.9%) CREC isolates produced ESBLs, which was higher than that of noncarbapenem-resistant Enterobacter cloacae (22, 23) . ESBL genes have been classified into 9 families based on their amino acid sequences (25) . TEM, SHV, and CTX-M are the most common families. In this study, SHV-12 (35.9%) was the main type and CTX-M was second (12.5%). Yang et al. (1) reported that SHV-12 accounted for 75.5% in ertapenem-resistant Enterobacter cloacae in Taiwan. Xia et al. (9) reported that CTX-M was the most common genotype (50.0%) in CREC in Chongqing in China. These results indicate that the genotype distribution of CREC is remarkably different in different countries and regions.
The resistance mechanisms of carbapenems are very complex and can be mediated by several means: 1) carbapenemase production, 2) production of ESBLs or AmpC β-lactamases associated with alterations in outer membrane proteins, and 3) hyperexpression of efflux systems (26) (27) (28) . Carbapenemase production is the most important carbapenem resistance mechanism in Enterobacteriaceae. In this study, 6 CREC isolates were not found to contain carbapenemase or ESBL genes, implying that resistance may involve other mechanisms not investigated in our study, such as production of other β-lactamases or hyperexpression of efflux systems.
Antimicrobial susceptibility testing showed that the CREC isolates all exhibited multidrug resistance. All isolates were either resistant or had intermediate susceptibility to beta-lactams, including carbapenems. Some isolates were only susceptible to aminoglycosides, quinolones, trimethoprim-sulfamethoxazole, tigecycline, and polymyxin. Current reports showed that only a minority of antibacterial drugs, such as tigecycline and polymyxin, can be first-line agents for treating carbapenem-resistant Enterobacteriaceae infections (29) . This finding indicates that the options for treating the infections caused by CREC are extremely limited. ESBLs and carbapenemases genes are commonly located on plasmids or other mobile genetic elements, which may harbor other antibiotic resistant genes, such as quinolones and aminoglycosides. These resistant genes can spread among bacteria together and then contribute to multiresistant phenotypes of CREC.
PFGE studies demonstrated that 3 isolates exhibited the same profile. They were all collected from the ICU department within 2 months and had the same drugresistant gene profile (SHV-12 + KPC-2) and antimicrobial susceptibility results, showing a possible clonal dissemination of 1 isolate. This finding demonstrated the potential epidemic threat of CREC in hospitals. The other isolates exhibited distinct PFGE profiles, indicating no obvious clonal association within them. It indicated that the infections caused by CREC were spontaneous in our hospital within the last 4 years. However, outbreaks of carbapenemase-producing Enterobacteriaceae have been reported in some hospitals (30) . Due to the fact that the infections with CREC are very difficult to treat and associated with high morbidity and mortality, it is necessary to monitor the emergence and spread of CREC strains.
There are at least 3 limitations of our study. First, we just selected a few common carbapenemase and ESBL enzymes to analyze. Some other types, such as GES, SME, and OXA, which were not detected in this study, might exist in these CREC isolates. Second, we did not detect loss of outer membrane proteins and efflux pump expression in these isolates, which may be involved in carbapenem resistance mechanisms. In addition, the number of CREC isolates was small, and further investigation should be done to verify the characteristics of CREC.
In summary, the infection rate of CREC has increased in recent years. Over 60% of CREC isolates had carbapenemase and/or ESBLs genes, and blaSHV-12 and blaKPC-2 were highly prevalent among them. Strict measures should be taken to control the spread of these pathogens in hospitals.
